NY-ESO-1 (157-165) C165V scrambled (MSILWQLVT)

NY-ESO-1 (157-165) C165V scrambled (MSILWQLVT) peptide can be used as a negative control of NY-ESO-1 (157-165) C165V variant epitope studies. Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein, including SLLMWITQC,that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members,its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8+ T cells. In order to better stimulate specific cytotoxic T-cells in PBMCs and analyze by ELISPOT peptide epitope,specificity,and cytokine production,like IFN-γ,SLLMWITQV variant peptide was used,as it is known to have a higher affinity for the binding cleft of the HLA-A*0201 complex than the native peptide. Moreover,SLLMWITQV has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165) C165V.